×
Log in
Upload File
Most Popular
Study
Business
Design
Technology
Travel
Explore all categories
Download -
oncoletter 2017/0… · Durvalumab + Tremelimumab vs Durvalumab vs Tremelimumab in I-ICC Arm + (n=36; 12 subjoctstviral status typo) ... ASCO 2016. Abstract 4012. 2017 Gastrointestinal
Download
Transcript
Page 1
Page 2
Page 3
Page 4
Page 5
Page 6
Page 7
Page 8
Page 9
Page 10
Page 11
Page 12
Page 13
Page 14
Page 15
Page 16
Page 17
Page 18
Page 19
Page 20
Page 21
Page 22
Page 23
Page 24
Page 25
Page 26
Page 27
Page 28
Page 29
Page 30
Page 31
Page 32
LOAD MORE
Top Related
SABCS 2018 - oncoletter · This presentation is the intellectual property of Contact for permission to repnnt and,'M distribute, ... Alpe isib e 10 12 14 16 18 Time (months) Endocrine
Olaparib and durvalumab in patients with germline BRCA ... · Web viewoccur in approximately 5% of breast cancer patients1,2 and are associated with high risk of cancer.3 BRCA proteins
Overview of and current indications for the use of immune ...images.researchtopractice.com/2017/Meetings/...Galsky et al. ESMO 2016 Sharma, et al. Lancet Oncology 2017. Durvalumab
SABCS 2019 - oncoletter · lcm (34%) O nodes tumor and/or pgR.ve (64%) pertuzumab ER.ve and/or (64%) ER-ve (36%) Placebo Placebo Pertuzumab Placebo Pertuzumab This presentation is
oncoletter · Cabozantinib TKI targeting VEGF receptors, MET, AXL, RET Improves PFS in advanced renal cell carcinoma in 1st line (vs. sunitinib)l and in 2nd line (vs. everolimus)
Pre0120-Greystoke Alastair · Pembrolizumab(MK-3475) Keytruda PD-1 MSD Atezolizumab (MPDL3280A) Tecentriq PD-L1 Roche Durvalumab(MEDI4736) Imfinzi PD-L1 AstraZeneca/Celgene ... Data
Presentación de PowerPoint€¦ · • Data cutoff date: August 1, 2016 Garassino, et al. WCLC 2016 (Abs. OA03.02) ... MYSTIC Durvalumab monotherapy or + tremelimumab (squamous and
News Briefing: Highlights from the 2018 Multidisciplinary ......EAGLE trial (NCT02369874) will assess the combination of durvalumab + tremelimumab and durvalumab monotherapy compared